Experiences and Lessons of Combating COVID-19 That Chinese Experts Shared with the World
Tao Liu,Jiufeng Sun,Miaoyun Wen,Youping Zhang,Xiaodan Luo,Xiangxin Liu,Shifang Yang,Jun Li
DOI: https://doi.org/10.46234/ccdcw2020.225
2020-01-01
China CDC Weekly
Abstract:At the end of 2019, a novel viral pneumonia was detected in Wuhan City (1) and has spread rapidly throughout 215 countries, areas, and territories with more than 3.8 million cases and over 260,000 deaths as of May 8, 2020. This pneumonia, later named coronavirus disease 2019 (COVID-19), has become a global public security challenge. The World Health Organization (WHO) has declared it a pandemic and has called for the global community to work collaboratively to combat this novel pneumonia (2). Since the early spread of COVID-19 in China, the Chinese government has implemented the most rigorous measures to prevent the spread of COVID-19 using the whole country’s medical resources (3). Until the end of March 2020, the COVID-19 pandemic was essentially under control in China (3). Unfortunately, some other countries had insufficient experience in the ramping up and deployment of public health measures including prevention tactics, interventions, laboratory tests, clinical diagnosis, and treatment, which has resulted in continued suffering due to COVID-19. In order to collaborate with these countries to contain the global pandemic, the Chinese government decided to send expert teams to several countries, including Iran, Iraq, Italy, Serbia, Cambodia, Pakistan, Laos, Venezuela, Ethiopia, and Malaysia, to assist in the prevention of local COVID-19 transmission beginning at the end of February. The experiences and lessons shared by Chinese experts were intended to serve as references for these countries to inform policies on prevention and control. As one of the expert teams, here we summarized the major experiences and lessons that were shared with many countries still affected by COVID-19. First, Chinese expert teams conducted field investigations and consulted with local governments, laboratory workers, health care workers, and citizens to collect information of the local situations of COVID19, laboratory testing capabilities, clinical treatment protocols, and control and prevention strategies and measures implemented. Then, they comprehensively assessed the situation and future trends of COVID-19 epidemic, which provided important information for them to communicate with local experts and to provide custom consultations for those countries. Second, based on the questions proposed by local experts, the Chinese experts introduced major prevention and control strategies and measures implemented in China including “four early measures”, “four priority measures”, “four necessary measures”, “three lines of defense”, applications of “health quick response (QR) codes”, and nonpharmaceutical intervention (NPI) measures (3). The “four early measures” includes early detection, reporting, isolation, and treatment of COVID-19 patients. The “four priority measures” includes concentrating patients, hospitals, experts, and treatment. The “four necessary measures” include all persons with need should be tested, admitted, treated, and isolated. The “three lines of defense” referred to joint travel quarantine at all travel stations including ports and wharfs, screening at hospitals, and management of focused population in communities. Applications of health QR codes involved monitoring and managing an individual’s health status by having each individual apply for a health QR code after submitting their health status online. QR codes contained three categories: green, yellow, and red. Individuals with green status can move freely without registering to enter public facilities. Those with yellow codes were quarantined, and those with red codes were isolated for further laboratory testing or treatment. The NPI mainly included restricting inter-city movement for individuals, the identification and isolation of cases, and the reduction of inner-city travel and of contact to ensure social distancing (4). Third, they shared clinical experiences on the diagnosis and treatment of COVID-19 patients. For example, they introduced the “Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia” in China (5). They also shared the usage of computed tomography (CT) scans for diagnosis of COVID-19 patients, selection of treatment drugs, treatment for pregnant women and newborns, zoning China CDC Weekly